

Injection Devices for Subcutaneous Self-administration

Devices, Markets,
Therapeutics, Strategies &
Forecasts

Report Brochure



Greystone
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Injection Devices for Subcutaneous Self-administration: Devices, Markets, Players, Strategies and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for subcutaneous injection devices. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.




Table of Contents

| | |
|--|---|
| Injection Devices for Subcutaneous Self-administration | Intevia (Becton Dickinson) |
| Executive Summary | Antares Pharma Autoinjectors |
| The Market Opportunity | Dali Medical Devices |
| Delivery Market Dynamics | Development-stage Autoinjectors |
| The Economics of Injectable Drugs | NIS Autoinjector (Midas Pharma) |
| What's Driving the Growth in Injectable Devices? | ArQ – Bios (Oval Medical) |
| Prefilled Syringes Proliferating | ArQ – Tempo (Oval Medical) |
| The Trend toward Self-Administration | ArQ – Vita (Oval Medical) |
| Shifting Demographics | Wirelessly Enabled Autoinjectors |
| Innovation in Disposable Device Designs | BETACONNECT (Bayer) |
| Proliferation of Biological Drugs | RebiSmart (Merck Serono) |
| Therapeutic Monoclonal Antibodies | Selected Product Specific Autoinjectors |
| Therapeutic Demand Drivers | Alsuma/Sumatriptan Autoinjector |
| Competitive Landscape | Sumatriptan (Dr. Reddy's) |
| Risk Factors | Rebif/Rebidose (Merck Serono) |
| Autoinjectors – Commercial Devices | Aimovig (Amgen/Novartis) |
| Manual Injection Autoinjectors | Enbrel Mini AutoTouch (Amgen) |
| Automated Injection Autoinjectors | Pegasys Proclick (Genentech/Roche) |
| Disposable Autoinjectors | Otrexup (Antares Pharma) |
| Molly (SHL Medical) | Evzio (Kaleo) |
| Molly RNS (SHL Medical) | Autoinjector Device Design Factors |
| Bertha (SHL Medical) | Material Selection Issues |
| Maggie (SHL Medical) | Part Counts and Device Cost |
| Amber (SHL Medical) | Safety Features |
| SafeLock (SHL Medical) | Needle Insertion Depth |
| VSDI +NIT (SHL Medical) | Failsafe Activation |
| SDI MIX +NIT (SHL Medical) | Dose Inspection/Injection Confirmation |
| Syrina S (Consort Medical) | Lyophilized Drugs/Reconstitution |
| Syrina AS (Consort Medical) | Human Engineering/Ergonomics |
| AutoJect 2 (Owen Mumford) | Pen Injectors |
| SelfDose (West Pharmaceutical Services) | Pen Injector Design Selection Factors |
| Flexi-Q PFS (Elcam Medical) | Standardized Pen Platforms |
| OTS Autoinjector (Consort Medical) | Haselmeier |
| Pro-Ject (Aptar) | Becton Dickinson |
| Consort Medical ASI | Owen Mumford |
| Ypsomed VarioJect | Autoject2 |
| Rotaject Technology (SHL Medical) | Ypsomed |
| Viscala Autoinjector (Consort Medical) | SHL Medical |
| Flexi-Q HV (Elcam Medical) | Custom Pen Designs |
| | Reusable Pens |
| | Dual Chamber Pens |
| | Commercial Pen Products |
| | Genotropin Pen |

Table of Contents (continued)

| | |
|--|-----------------------------------|
| Humatro-Pen/Humatro Pen 3 | Rheumatoid Arthritis |
| Norditropin | Psoriasis |
| NordiPenmate | Multiple Sclerosis |
| Nutropin AQ Pen | Exenatide (Byetta) |
| Omnitrope | Bydureon |
| One.Click | Pramlintide (Symlin) |
| Lantus/Toujeo (Insulin Glargine) | Abliglutide (Tanzeum) |
| Diapen | Hepatitis |
| Gansulin Pen | Hormones |
| Flexpen (Novo Nordisk) | Osteoporosis |
| Humalog Pen/KwikPen | Market Factors |
| HumaPen Memoir | Regulatory Issues |
| HumaPen Luxura HD | Device Branding |
| NovoPen (Novo Nordisk) | Patient Adherence and Ease of Use |
| SoloStar | Healthcare Economics |
| Byetta Pen | Company Profiles |
| Bydureon | |
| SymlinPen | |
| Saxenda (Liraglutide) | |
| Tanzeum (Abliglutide) | |
| Trulicity (Dulaglutide) | |
| Victoza (Liraglutide) | |
| Parathyroid Hormone | |
| Forteo Pen | |
| Preotact/Preos | |
| Natpara | |
| Reproductive Hormones | |
| Follistim/Puregon Pen | |
| Gonal-f | |
| Wearable Devices - Product Analysis and Assessments | |
| Libertas (Becton Dickinson) | |
| Patch Pump (Sensile Medical) | |
| SmartDose (West Pharmaceuticals) | |
| Neulasta OnPro Injector (Insulet/Amgen) | |
| YpsuDose (Ypsomed) | |
| Electronic Semi-disposable E3D Patch Pump (Elcam) | |
| Mechanical Disposable enFuse (Enable Injections) | |
| Captive Devices | |
| sc2Wear Infusor (scPharmaceuticals) | |
| PatchPump (SteadyMed) | |
| Wireless Data | |
| Key Therapeutic Sector Analysis | |
| Anaphylaxis/Countermeasures | |
| Autoimmune Diseases | |

What You Will Learn

- Provides detailed analysis of subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2028
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factor

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-440-5710, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Research Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Injection Devices for Subcutaneous Self-administration

Devices, Markets, Therapeutics, Strategies and Forecasts

| Select | Format | License | Price (U.S. Funds) | Total |
|-----------------------------------|--------|---------------------|--------------------|-------|
| <input type="checkbox"/> | PDF | Single User License | \$4,850.00 | |
| <input type="checkbox"/> | PDF | Site License | \$6,500.00 | |
| <input type="checkbox"/> | PDF | Global License | \$9,500.00 | |
| Total Payment (U.S. funds) | | | | |

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

| Billing Information | Shipping Information |
|----------------------|---|
| Name: | <input type="checkbox"/> Click here if same as Billing Information Name: |
| Title: | Title: |
| Company: | Company: |
| Street Address: | Street Address: |
| City,State/Province: | City,State/Province: |
| Country/Postal Code: | Country/Postal Code: |
| Phone: | Phone: |
| Fax: | Fax: |
| Email: | Email: |